(AOF) – Bristol Myers Squibb is expected to decline in pre-market trading on Wall Street after having postponed by one year, from 2025 to 2026, its objective of exceeding $10 billion in turnover linked to new products . The American laboratory, however, posted adjusted earnings per share of $2 in the third quarter versus $1.76 expected, which led it to raise its annual forecast from $7.35-7.65 to $7.50-7.65. . Additionally, its quarterly revenue was in line with expectations amounting to $10.96 billion.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
